OGI invests in Rna Diagnostics
TORONTO—The Ontario Genomics Institute (OGI) has announced an investment, through its Pre-Commercialization Business Development Fund, in Rna Diagnostics Inc., an early-stage molecular diagnostics company developing assays to assist in chemotherapy management. The funding will help Rna Diagnostics develop and validate its lead product, the RNA Disruption Assay. The assay will aid in determining whether a patient is responding to therapy earlier in the course of treatment than current methods.
“One of the key aims of personalized medicine is to provide the right medicine to the right patient at the right time. This assay monitors molecular data from a particular patient to help inform clinical decisions for that patient,” Dr. Mark Poznansky, president and CEO of OGI, said in a statement. “Rna Diagnostics has the potential to create innovative products for the Canadian healthcare system and beyond.”